Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | IRAK2 |
| Gene Name: | IRAK2 |
| Protein Full Name: | Interleukin-1 receptor-associated kinase-like 2 |
| Mass (Da): | 69433 |
| Number AA: | 625 |
| UniProt ID: | O43187 |
| Locus ID: | 3656 |
| COSMIC ID: | IRAK2 |
| Gene location on chromosome: | 3p25.3 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19535 |
| Percent of cancer specimens with mutations: | 0.59 |
| Normal role description: | IRAK2 is a protein-serine/threonine kinase which associates with the interleukin-1 receptor (IL1) upon IL1 binding. IRAK2 will lead to activation of NF-kB. Although possessing a protein kinase domain IRAK2 is predicted to be catalytically inactive. IRAK2 is also associated with toll-like receptor (TLR) signalling and can associate with MYD88 and TRIF. IRAK2's role in cancer development is still largely unknown. Due to its regulation of NF-kB activation IRAK2 maybe an important therapeutic target in NF-kB mediated cancers. Mis-sense mutations have been observed in lung adenocarcinomas but their functional effect is uncharacterized. |
| Commentary on involvement of protein in cancer: | Less than 3% mutations in lung cancer. |